Risk Factor Analysis of Thymoma Resection and Its Value in Guiding Clinical Treatment

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 May 8

PMID 37156630

Authors

Xin Du

Jian Cui

Xin-Tao Yu

Lei Yu

Affiliations

Soon will be listed here.

Abstract

Background: In this study, relationships between clinicopathologic characteristics and progression-free survival (PFS) of patients after thymomectomy were analyzed to provide valuable suggestions regarding the treatment of thymoma.

Methods: Data from 187 thymoma patients undergoing surgery at Beijing Tongren Hospital between January 1, 2006, and December 31, 2015, were retrospectively reviewed. We explored the risk factors for PFS among sex, age, thymoma-associated MG, completeness of resection, histologic type and TNM stage, and investigated their interrelationship.

Results: Among the 187 patients, 18 patients (9.63%) had tumor recurrence/metastasis, and all of whom had in situ recurrence or pleural metastasis, and most of them (10 of 18 patients) had MG symptoms that reappeared or were aggravated. Fifteen patients (8.02%) died, and myasthenic crisis was a leading cause. Based on Cox regression analysis, only age (HR = 3.16; 95% CI: 1.44-6.91; p = 0.004) and the completeness of resection (HR = 9.03; 95% CI: 2.58-31.55; p = 0.001) were independent risk factors for PFS. Furthermore, we found that the completeness of resection was related to the histologic type (p = 0.009) and TNM stage (p < 0.001) by Fisher's exact test.

Conclusions: The results of this cohort study remind us that we should pay attention to the reappearance or aggravation of MG after thymoma resection, because it is the leading cause of death and may indicate tumor progression. Furthermore, completeness of resection was related to the histologic type and TNM stage, but it was the independent risk factors of thymoma. Therefore, R0 resection is critical to the prognosis of thymoma.

Citing Articles

Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study.

Jin L, He D, Zeng Q, Tan S, Shi J, Liu Y Ther Adv Neurol Disord. 2024; 17:17562864241309431.

PMID: 39735403 PMC: 11672488. DOI: 10.1177/17562864241309431.

Risk factor analysis of thymoma resection and its value in guiding clinical treatment.

Du X, Cui J, Yu X, Yu L Cancer Med. 2023; 12(12):13408-13414.

PMID: 37156630 PMC: 10315718. DOI: 10.1002/cam4.6043.

References

Attaran S, McCormack D, Pilling J, Harrison-Phipps K . Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy?. Interact Cardiovasc Thorac Surg. 2012; 15(2):273-5. PMC: 3397733. DOI: 10.1093/icvts/ivs133. View

Nakagawa K, Asamura H, Matsuno Y, Suzuki K, Kondo H, Maeshima A . Thymoma: a clinicopathologic study based on the new World Health Organization classification. J Thorac Cardiovasc Surg. 2003; 126(4):1134-40. DOI: 10.1016/s0022-5223(03)00798-0. View

Ried M, Potzger T, Sziklavari Z, Diez C, Neu R, Schalke B . Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome. Thorac Cardiovasc Surg. 2013; 62(2):161-8. DOI: 10.1055/s-0033-1345303. View

Zhao Y, Shi J, Fan L, Hu D, Yang J, Zhao H . Surgical treatment of thymoma: an 11-year experience with 761 patients. Eur J Cardiothorac Surg. 2015; 49(4):1144-9. DOI: 10.1093/ejcts/ezv288. View

Kondo K . Optimal therapy for thymoma. J Med Invest. 2008; 55(1-2):17-28. DOI: 10.2152/jmi.55.17. View

Utsumi T, Shiono H, Kadota Y, Matsumura A, Maeda H, Ohta M . Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer. 2009; 115(23):5413-20. DOI: 10.1002/cncr.24618. View

Marx A, Chan J, Chalabreysse L, Dacic S, Detterbeck F, French C . The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. J Thorac Oncol. 2021; 17(2):200-213. DOI: 10.1016/j.jtho.2021.10.010. View

Detterbeck F, Zeeshan A . Thymoma: current diagnosis and treatment. Chin Med J (Engl). 2013; 126(11):2186-91. View

Hamaji M, Shah R, Ali S, Bettenhausen A, Lee H, Burt B . A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma. Ann Thorac Surg. 2017; 103(5):1668-1675. DOI: 10.1016/j.athoracsur.2016.12.042. View

10.

Cho J, Kim H, Ku B, Choi Y, Cristescu R, Han J . Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2018; 37(24):2162-2170. DOI: 10.1200/JCO.2017.77.3184. View

11.

Thomas C, Wright C, Loehrer P . Thymoma: state of the art. J Clin Oncol. 1999; 17(7):2280-9. DOI: 10.1200/JCO.1999.17.7.2280. View

12.

Marom E . Imaging thymoma. J Thorac Oncol. 2010; 5(10 Suppl 4):S296-303. DOI: 10.1097/JTO.0b013e3181f209ca. View

13.

Bretti S, Berruti A, Loddo C, Sperone P, Casadio C, Tessa M . Multimodal management of stages III-IVa malignant thymoma. Lung Cancer. 2004; 44(1):69-77. DOI: 10.1016/j.lungcan.2003.09.022. View

14.

Detterbeck F, Youssef S, Ruffini E, Okumura M . A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011; 6(7 Suppl 3):S1698-704. DOI: 10.1097/JTO.0b013e31821e7b12. View

15.

Siesling S, van der Zwan J, Izarzugaza I, Jaal J, Treasure T, Foschi R . Rare thoracic cancers, including peritoneum mesothelioma. Eur J Cancer. 2012; 48(7):949-60. DOI: 10.1016/j.ejca.2012.02.047. View

16.

Kondo K, Monden Y . Thymoma and myasthenia gravis: a clinical study of 1,089 patients from Japan. Ann Thorac Surg. 2004; 79(1):219-24. DOI: 10.1016/j.athoracsur.2004.06.090. View

17.

Okumura M, Miyoshi S, Takeuchi Y, Yoon H, Minami M, Takeda S . Results of surgical treatment of thymomas with special reference to the involved organs. J Thorac Cardiovasc Surg. 1999; 117(3):605-13. DOI: 10.1016/s0022-5223(99)70343-0. View

18.

Girard N, Lal R, Wakelee H, Riely G, Loehrer P . Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol. 2011; 6(7 Suppl 3):S1749-55. DOI: 10.1097/JTO.0b013e31821ea5f7. View

19.

Strobel P, Hohenberger P, Marx A . Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010; 5(10 Suppl 4):S286-90. DOI: 10.1097/JTO.0b013e3181f209a8. View

20.

Du X, Cui J, Yu X, Yu L . Risk factor analysis of thymoma resection and its value in guiding clinical treatment. Cancer Med. 2023; 12(12):13408-13414. PMC: 10315718. DOI: 10.1002/cam4.6043. View